TABLE 2.
Patient no. | VL (copies/ml)
|
Doubling time (days) during STI:
|
First-phase decay half-life (days) after STI:
|
Second-phase decay half-life (days) after STI:
|
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pretreatment | Plateau | 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | |
1 | 561,831 | 76,805 | 1.18 | 1.24 | 1.15 | 2.10 | 1.49 | 1.48 | 1.42 | 1.52 | NAa | 15.53 | 18.85 | 27.31 | 15.11 |
2 | 80,600 | 21,393 | NA | NA | NA | NA | 1.33 | NA | NA | NA | NA | NA | NA | NA | NA |
3 | 34,752 | 115,546 | 0.78 | 1.31 | 1.26 | 1.33 | 1.33 | 3.06 | 1.98 | 2.26 | 1.77 | 16.32 | 16.35 | 10.57 | 15.19 |
4 | 122,729 | 19,344 | 1.04 | 1.21 | 1.25 | 1.29 | 1.35 | 2.26 | 1.23 | 2.21 | 1.93 | 12.06 | 8.80 | 10.05 | 11.14 |
5 | 32,140 | 6,459 | 10.26 | 4.89 | 1.52 | 1.13 | 3.56 | 2.10 | 1.42 | 1.49 | 1.78 | NA | NA | 18.19 | 14.01 |
6 | 467,598 | 31,500 | 1.06 | 0.85 | 1.28 | 1.38 | 1.25 | 1.61 | 1.18 | 1.59 | 1.26 | 13.12 | 10.92 | 14.83 | 10.65 |
7 | 16,927 | 3,140 | 0.95 | 1.01 | 1.99 | 1.21 | 1.48 | 1.16 | 1.94 | NA | 1.07 | 1,664.09 | 6.05 | NA | 14.08 |
8 | 150,390 | 40,176 | 3.67 | 1.74 | 8.00 | 3.31 | 1.35 | 5.63 | 2.05 | 14.27 | 1.88 | 32.94 | −95.31 | 11.20 | NA |
9 | 164,772 | 65,941 | 1.38 | 1.46 | 3.18 | 2.36 | 1.78 | 1.94 | 1.02 | 17.69 | NA | 9.70 | 18.88 | 12.40 | 11.76 |
10 | 11,298 | 4,623 | 1.97 | 7.86 | 3.67 | 1.26 | 3.58 | 2.00 | 2.13 | 1.38 | 1.24 | −48.28 | NA | NA | NA |
11 | 25,417 | 106,928 | 2.01 | 2.15 | 2.73 | 2.46 | 3.16 | 2.22 | 8.48 | 1.98 | 3.54 | −72.05 | 19.87 | −20.33 | −57.25 |
12 | 9,404 | 20,236 | 1.00 | 1.25 | 0.99 | 2.86 | 7.65 | 1.17 | 1.37 | NA | 1.88 | 14.87 | 13.17 | 21.65 | 21.15 |
13 | 537 | 105 | NA | NA | NA | NA | 1.86 | NA | NA | NA | NA | NA | NA | NA | NA |
Mean | 2.30 | 2.27 | 2.46 | 1.88 | 2.40 | 2.24 | 2.20 | 4.93 | 1.82 | 165.83 | 1.96 | 11.76 | 6.20 |
NA, not available (either no rebound was observed during the 2-week STI or not enough data points were available to calculate first- and second-phase half-lives).